Tissue Engineering and Stem Cell Group, Singapore Eye Research Institute, Singapore, Singapore.
Singapore National Eye Centre, Singapore, Singapore.
Sci Rep. 2018 Jan 30;8(1):1831. doi: 10.1038/s41598-018-20267-7.
Corneal inlays are a relatively new treatment option for presbyopia. Using biological inlays, derived from lenticules extracted from small incision lenticule extraction, may offer advantages over commercialized synthetic inlays in the aspect of biocompatibility. We conducted a non-human primate study to evaluate the safety, predictability, efficacy and tissue response after autogeneic, decellularized xenogeneic and xenogeneic lenticule implantation. The lenticule implantation effectively resulted in central corneal steepening (simulated keratometric values increased by 1.8-2.3 diopters), central hyper-prolate changes (asphericity Q values changed by -0.26 to -0.36), corneal anterior surface elevation (7.7-9.3 μm) and reasonable effective zone (1.5-1.8 times of the lenticule physical diameter), with no differences among the three groups. Slit lamp microscopy, transmission electron microscopy, confocal microscopy, histology and immunohistochemistry analyses confirmed the biocompatibility of the autogeneic and decellularized lenticules, whereas one eye in the xenogeneic group developed corneal stromal rejection during the study period. Our results showed that lenticule implantation has the potential for the management of presbyopia, and provide the basis for future clinical studies. The decellularization process may increase the potential utilization of lenticules without changing the efficacy.
角膜内植入物是治疗远视的一种相对较新的治疗选择。使用源自小切口微透镜提取术提取的微透镜的生物内植入物在生物相容性方面可能优于商业化的合成内植入物。我们进行了一项非人类灵长类动物研究,以评估同种异体、去细胞化异种和异种微透镜植入后的安全性、可预测性、疗效和组织反应。微透镜植入有效地导致中央角膜变陡(模拟角膜曲率值增加 1.8-2.3 屈光度)、中央高扁度变化(非球面 Q 值变化-0.26 至-0.36)、角膜前表面抬高(7.7-9.3μm)和合理的有效区(微透镜物理直径的 1.5-1.8 倍),三组之间无差异。裂隙灯显微镜、透射电子显微镜、共聚焦显微镜、组织学和免疫组织化学分析证实了同种异体和去细胞化微透镜的生物相容性,而异种组中的一只眼睛在研究期间发生了角膜基质排斥反应。我们的结果表明,微透镜植入术具有治疗远视的潜力,并为未来的临床研究提供了依据。去细胞化过程可能会增加微透镜的潜在用途,而不会改变疗效。